Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Susie Jun, Karim Fizazi et al.|European Journal of Cancer|2012Cited by 588
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Aude Fléchon et al.|Nature Medicine|2021Cited by 115
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of ActionIgnacio Durán, Oriol Casanovas, J. Lambea et al.|Targeted Oncology|2016Cited by 103